Survival Benefit With Lenvima/Keytruda for Advanced Clear Cell RCC Continues After 4 Years

After a median follow-up of four years, the survival benefit, including progression-free survival persisted in patients with advanced clear cell renal cell carcinoma treated with Lenvima plus Keytruda compared with those treated with Sutent.

Related Keywords

Lenvima Keytruda ,Thomase Hutson ,Treatment Center At Baylor University Medical ,Urologic Cancer Research ,Treatment Center ,Baylor University Medical ,Asco Annual Conference ,Kidney Cancer ,